Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer
Authors:
- Risa WakisakaRWRisa Wakisaka
- Hidekiyo YamakiHYHidekiyo Yamaki
- Michihisa KonoMKMichihisa Kono
- Takahiro InoueTITakahiro Inoue
- Ryosuke SatoRSRyosuke Sato
- Hiroki KomatsudaHKHiroki Komatsuda
- Kenzo OharaKOKenzo Ohara
- Akemi KosakaAKAkemi Kosaka
- Takayuki OhkuriTOTakayuki Ohkuri
- Toshihiro NagatoTNToshihiro Nagato
- Kan KishibeKKKan Kishibe
- Koh NakayamaKNKoh Nakayama
Open Access
Abstract
Intratumoral hypoxia is associated with tumor progression, aggressiveness, and therapeutic resistance in several cancers. Hypoxia causes cancer cells to experience replication stress, thereby activating DNA damage and repair pathways. MutT homologue-1 (MTH1, also known as NUDT1), a member of the Nudix family, maintains the genomic integrity and viability of tumor cells in the hypoxic tumor microenvironment. Although hypoxia is associated with poor prognosis and can cause therapeutic resistance by regulating the microenvironment, it has not been considered a treatable target in cancer. This study aimed to investigate whether hypoxia-induced MTH1 is a useful target for immunotherapy and whether hypoxic conditions influence the antitumor activity of immune cells. Our results showed that MTH1 expression was elevated under hypoxic conditions in head and neck cancer cell lines. Furthermore, we identified a novel MTH1-targeting epitope peptide that can activate peptide-specific CD4+ helper T cells with cytotoxic activity. The proliferation and cytotoxic activity of T cells were maintained under hypoxic conditions, and PD-1 blockade further augmented the cytotoxicity. These results indicate that MTH1-targeted immunotherapy combined with checkpoint blockade can be an effective strategy for the treatment of hypoxic tumors.Keywords
Funding Information
- Japan Society for the Promotion of Science (23K08929, 23K08977)
This publication has 52 references indexed in Scilit:
- Immunotherapy targeting tumor‐associated antigen in a mouse model of head and neck cancerHead & Neck, 2024
- The high expression of MTH1 and NUDT5 promotes tumor metastasis and indicates a poor prognosis in patients with non-small-cell lung cancerBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2021
- Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectivesActa Pharmaceutica Sinica B, 2020
- Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissueDNA Repair, 2019
- Evolutionary Pressure against MHC Class II Binding Cancer MutationsCell, 2018
- Culturing CTLs under Hypoxic Conditions Enhances Their Cytolysis and Improves Their Anti-tumor FunctionCell Reports, 2017
- HIF-1α pathway: role, regulation and intervention for cancer therapyActa Pharmaceutica Sinica B, 2015
- Hypoxia in Tumors: Pathogenesis-Related Classification, Characterization of Hypoxia Subtypes, and Associated Biological and Clinical Implications2014
- The role of hypoxia-inducible factors in cancerCellular and Molecular Life Sciences, 2007
- Hypoxia in cancer: significance and impact on clinical outcomeCancer and Metastasis Reviews, 2007